Biomarkers, Bundled Payments, and Colorectal Cancer Care

William Ross, Patrick Lynch, Gottumukkala Raju, Alma Rodriguez, Thomas Burke, Lisa Hafemeister, Ernest Hawk, Xifeng Wu, Raymond N. DuBois, Lopa Mishra

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Changes in the management of cancers such as colorectal cancer (CRC) are urgently needed, as such cancers continue to be one of the most commonly diagnosed cancers; CRC accounts for 21% of all cancers and is responsible for mortalities second only to lung cancer in the United States. A comprehensive science-driven approach towards markedly improved early detection/screening to efficacious targeted therapeutics with clear diagnostic and prognostic markers is essential. In addition, further changes addressing rising costs, stemming from recent health care reform measures, will be brought about in part by changes in how care is reimbursed. For oncology, the advances in genomics and biomarkers have the potential to define subsets of patients who have a prognosis or response to a particular type of therapy that differs from the mean. Better definition of a cancer's behavior will facilitate developing care plans tailored to the patient. One method under study is episode-based payment or bundling, where one payment is made to a provider organization to cover all expenses associated with a discrete illness episode. Payments will be based on the average cost of care, with providers taking on a risk for overutilization and outliers. For providers to thrive in this environment, they will need to know what care a patient will require and the costs of that care. A science-driven "personalized approach" to cancer care has the potential to produce better outcomes with reductions in the use of ineffectual therapies and costs. This promising scenario is still in the future, but progress is being made, and the shape of things to come for cancer care in the age of genomics is becoming clearer.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalGenes and Cancer
Volume3
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Biomarkers
Neoplasms
Costs and Cost Analysis
Genomics
Health Care Reform
Lung Neoplasms
Patient Care
Therapeutics
Organizations
Mortality

Keywords

  • biomarkers
  • bundled payments
  • colorectal cancer
  • health care reform
  • health policy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Ross, W., Lynch, P., Raju, G., Rodriguez, A., Burke, T., Hafemeister, L., ... Mishra, L. (2012). Biomarkers, Bundled Payments, and Colorectal Cancer Care. Genes and Cancer, 3(1), 16-22. https://doi.org/10.1177/1947601912448958

Biomarkers, Bundled Payments, and Colorectal Cancer Care. / Ross, William; Lynch, Patrick; Raju, Gottumukkala; Rodriguez, Alma; Burke, Thomas; Hafemeister, Lisa; Hawk, Ernest; Wu, Xifeng; DuBois, Raymond N.; Mishra, Lopa.

In: Genes and Cancer, Vol. 3, No. 1, 01.2012, p. 16-22.

Research output: Contribution to journalArticle

Ross, W, Lynch, P, Raju, G, Rodriguez, A, Burke, T, Hafemeister, L, Hawk, E, Wu, X, DuBois, RN & Mishra, L 2012, 'Biomarkers, Bundled Payments, and Colorectal Cancer Care', Genes and Cancer, vol. 3, no. 1, pp. 16-22. https://doi.org/10.1177/1947601912448958
Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hafemeister L et al. Biomarkers, Bundled Payments, and Colorectal Cancer Care. Genes and Cancer. 2012 Jan;3(1):16-22. https://doi.org/10.1177/1947601912448958
Ross, William ; Lynch, Patrick ; Raju, Gottumukkala ; Rodriguez, Alma ; Burke, Thomas ; Hafemeister, Lisa ; Hawk, Ernest ; Wu, Xifeng ; DuBois, Raymond N. ; Mishra, Lopa. / Biomarkers, Bundled Payments, and Colorectal Cancer Care. In: Genes and Cancer. 2012 ; Vol. 3, No. 1. pp. 16-22.
@article{18e3e95226df49019c3bc07671e711aa,
title = "Biomarkers, Bundled Payments, and Colorectal Cancer Care",
abstract = "Changes in the management of cancers such as colorectal cancer (CRC) are urgently needed, as such cancers continue to be one of the most commonly diagnosed cancers; CRC accounts for 21{\%} of all cancers and is responsible for mortalities second only to lung cancer in the United States. A comprehensive science-driven approach towards markedly improved early detection/screening to efficacious targeted therapeutics with clear diagnostic and prognostic markers is essential. In addition, further changes addressing rising costs, stemming from recent health care reform measures, will be brought about in part by changes in how care is reimbursed. For oncology, the advances in genomics and biomarkers have the potential to define subsets of patients who have a prognosis or response to a particular type of therapy that differs from the mean. Better definition of a cancer's behavior will facilitate developing care plans tailored to the patient. One method under study is episode-based payment or bundling, where one payment is made to a provider organization to cover all expenses associated with a discrete illness episode. Payments will be based on the average cost of care, with providers taking on a risk for overutilization and outliers. For providers to thrive in this environment, they will need to know what care a patient will require and the costs of that care. A science-driven {"}personalized approach{"} to cancer care has the potential to produce better outcomes with reductions in the use of ineffectual therapies and costs. This promising scenario is still in the future, but progress is being made, and the shape of things to come for cancer care in the age of genomics is becoming clearer.",
keywords = "biomarkers, bundled payments, colorectal cancer, health care reform, health policy",
author = "William Ross and Patrick Lynch and Gottumukkala Raju and Alma Rodriguez and Thomas Burke and Lisa Hafemeister and Ernest Hawk and Xifeng Wu and DuBois, {Raymond N.} and Lopa Mishra",
year = "2012",
month = "1",
doi = "10.1177/1947601912448958",
language = "English (US)",
volume = "3",
pages = "16--22",
journal = "Genes and Cancer",
issn = "1947-6019",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Biomarkers, Bundled Payments, and Colorectal Cancer Care

AU - Ross, William

AU - Lynch, Patrick

AU - Raju, Gottumukkala

AU - Rodriguez, Alma

AU - Burke, Thomas

AU - Hafemeister, Lisa

AU - Hawk, Ernest

AU - Wu, Xifeng

AU - DuBois, Raymond N.

AU - Mishra, Lopa

PY - 2012/1

Y1 - 2012/1

N2 - Changes in the management of cancers such as colorectal cancer (CRC) are urgently needed, as such cancers continue to be one of the most commonly diagnosed cancers; CRC accounts for 21% of all cancers and is responsible for mortalities second only to lung cancer in the United States. A comprehensive science-driven approach towards markedly improved early detection/screening to efficacious targeted therapeutics with clear diagnostic and prognostic markers is essential. In addition, further changes addressing rising costs, stemming from recent health care reform measures, will be brought about in part by changes in how care is reimbursed. For oncology, the advances in genomics and biomarkers have the potential to define subsets of patients who have a prognosis or response to a particular type of therapy that differs from the mean. Better definition of a cancer's behavior will facilitate developing care plans tailored to the patient. One method under study is episode-based payment or bundling, where one payment is made to a provider organization to cover all expenses associated with a discrete illness episode. Payments will be based on the average cost of care, with providers taking on a risk for overutilization and outliers. For providers to thrive in this environment, they will need to know what care a patient will require and the costs of that care. A science-driven "personalized approach" to cancer care has the potential to produce better outcomes with reductions in the use of ineffectual therapies and costs. This promising scenario is still in the future, but progress is being made, and the shape of things to come for cancer care in the age of genomics is becoming clearer.

AB - Changes in the management of cancers such as colorectal cancer (CRC) are urgently needed, as such cancers continue to be one of the most commonly diagnosed cancers; CRC accounts for 21% of all cancers and is responsible for mortalities second only to lung cancer in the United States. A comprehensive science-driven approach towards markedly improved early detection/screening to efficacious targeted therapeutics with clear diagnostic and prognostic markers is essential. In addition, further changes addressing rising costs, stemming from recent health care reform measures, will be brought about in part by changes in how care is reimbursed. For oncology, the advances in genomics and biomarkers have the potential to define subsets of patients who have a prognosis or response to a particular type of therapy that differs from the mean. Better definition of a cancer's behavior will facilitate developing care plans tailored to the patient. One method under study is episode-based payment or bundling, where one payment is made to a provider organization to cover all expenses associated with a discrete illness episode. Payments will be based on the average cost of care, with providers taking on a risk for overutilization and outliers. For providers to thrive in this environment, they will need to know what care a patient will require and the costs of that care. A science-driven "personalized approach" to cancer care has the potential to produce better outcomes with reductions in the use of ineffectual therapies and costs. This promising scenario is still in the future, but progress is being made, and the shape of things to come for cancer care in the age of genomics is becoming clearer.

KW - biomarkers

KW - bundled payments

KW - colorectal cancer

KW - health care reform

KW - health policy

UR - http://www.scopus.com/inward/record.url?scp=84868642293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868642293&partnerID=8YFLogxK

U2 - 10.1177/1947601912448958

DO - 10.1177/1947601912448958

M3 - Article

C2 - 22893787

AN - SCOPUS:84868642293

VL - 3

SP - 16

EP - 22

JO - Genes and Cancer

JF - Genes and Cancer

SN - 1947-6019

IS - 1

ER -